Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1731 | High dose Interferon-beta 1a Wiki | 1.00 |
| drug2154 | Lopinavir Wiki | 1.00 |
| drug2192 | Low dose Interferon-beta 1a Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
This study seeks to determine whether dual or quadruple therapy is more effective in treating COVID-19.
Description: Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.
Measure: Efficacy of Treatment by Reduced Symptoms NEWS (National Early Warning System) scores Time: 6 monthsDescription: Time to non-infectivity as measured by PCR testing
Measure: Efficacy of Treatment by Time to Non-Infectivity Time: 10 daysDescription: Patient symptoms will be recorded using the NEWS system, which rates patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.
Measure: Safety of Dual Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) sores Time: 6 monthsDescription: Patient symptoms will be recorded using the NEWS system, which rates patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.
Measure: Safety of Quadruple Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) scores. Time: 6 monthsDescription: Changes in blood parameters measured in a Complete Blood Count (CBC).
Measure: Safety of Dual Therapy as Measured by Complete Blood Count Time: 6 monthsDescription: Changes in blood parameters measured in a Complete Metabolic Panel.
Measure: Safety of Quadruple Therapy as Measured by Complete Blood Count Time: 6 monthsDescription: Changes in serum albumin levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel -Albumin Time: 6 monthsDescription: Changes in serum albumin levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - Albumin Time: 6 monthsDescription: Changes in serum albumin/globulin ratio
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - A/G Ratio Time: 6 monthsDescription: Changes in serum albumin/globulin ratio
Measure: Safety of Dual Therapy as Measured by Metabolic Panel A/G Ratio Time: 6 monthsDescription: Changes in serum alkaline phosphatase levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - Alkaline Phosphatase Time: 6 monthsDescription: Changes in serum alkaline phosphatase levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel Alkaline Phosphatase Time: 6 monthsDescription: Changes in serum AST levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel - AST Time: 6 monthsDescription: Changes in serum AST levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - AST Time: 6 monthsDescription: Changes in serum ALT levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - ALT Time: 6 monthsDescription: Changes in serum ALT levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel ALT Time: 6 monthsDescription: Changes in serum BUN/Creatinine Ratio
Measure: Safety of Dual Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio Time: 6 monthsDescription: Changes in serum BUN/Creatinine Ratio
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio Time: 6 monthsDescription: Changes in serum Blood Urea Nitrogen levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - BUN Time: 6 monthsDescription: Changes in serum Blood Urea Nitrogen levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel - BUN Time: 6 monthsDescription: Changes in serum calcium levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel - Calcium Time: 6 monthsDescription: Changes in serum calcium levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - Calcium Time: 6 monthsDescription: Changes in serum carbon dioxide levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - Carbon Dioxide Time: 6 monthsDescription: Changes in serum carbon dioxide levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel - Carbon Dioxide Time: 6 monthsDescription: Changes in serum chloride levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel - Chloride Time: 6 monthsDescription: Changes in serum chloride levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - Chloride Time: 6 monthsDescription: Changes in serum creatinine levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - Creatinine Time: 6 monthsDescription: Changes in serum creatinine levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel - Creatinine Time: 6 monthsDescription: Changes in serum globulin levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel - Globulin Time: 6 monthsDescription: Changes in serum globulin levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - Globulin Time: 6 monthsDescription: Changes in blood glucose levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - Glucose Time: 6 monthsDescription: Changes in blood glucose levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel - Glucose Time: 6 monthsDescription: Changes in blood potassium levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel - Potassium Time: 6 monthsDescription: Changes in blood potassium levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - Potassium Time: 6 monthsDescription: Changes in serum total bilirubin levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Bilirubin Time: 6 monthsDescription: Changes in serum total bilirubin levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel - Total Bilirubin Time: 6 monthsDescription: Changes in serum total protein levels
Measure: Safety of Dual Therapy as Measured by Metabolic Panel - Total Protein Time: 6 monthsDescription: Changes in serum total protein levels
Measure: Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Protein Time: 6 monthsDescription: Presence or absence of treatment related serious adverse events Grade III or higher
Measure: Safety of Dual Therapy as Measured by Treatment Related SAE Time: 6 monthsDescription: Presence or absence of treatment related serious adverse events Grade III or higher
Measure: Safety of Quadruple Therapy as Measured by Treatment Related SAE Time: 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports